Elixir Medical Corporation

We are thrilled that the #DynamX bioadaptor animation, developed in collaboration with Kadiko, was recently honored in the 2024 Telly Awards.    🥇 Gold Winner in the Pharmaceuticals – Non-Broadcast Category    🥈 Silver Winner in the Craft-3D Animation Category    The combo of human anatomy visuals and detailed method of action creates a realistic portrayal of the #bioadaptor enabling vessel pulsatility in action.    Watch the award-winning animation here: https://lnkd.in/emHYRQqE   #Bioadaptor #Medtech #Innovation #Cardiology    CE marked. Not for sale in the U.S.   PMN 1890 REV A

📣 Our #DynamX Sirolimus-Eluting Coronary #Bioadaptor System has been granted Breakthrough Device Designation by the FDA for the treatment of symptomatic ischemic heart disease. Learn more here: https://lnkd.in/ehVvSY5R #Medtech #Innovation #Cardiology CE marked. Not for sale in the U.S. PMN 1892 REV A

DynamX shows excellent performance with “the rate of target lesion failure essentially unchanged over time.” - TCTMD “The study suggests “an edge” with Bioadaptor in terms of TLF over the drug-eluting stent.” - Professor Robert Byrne. Read more about the #BIOADAPTOR RCT two-year data presented at #EuroPCR in a recent article from Michael O'Riordan in TCTMD: https://lnkd.in/e5EiHPU4     Dr. Stefan Verheye Dr. Mirvat Alasnag   #Bioadaptor #Medtech #Innovation #Cardiology CE marked. Not approved in the U.S. PMN 1887 REV A

ICYMI: At #EuroPCR 2024, we presented late-breaking clinical results from the DESyne® BDS Plus Randomized Controlled Trial (RCT) that demonstrated the safety and efficacy of the innovative site specific anti-thrombotic drug therapy (TRx) platform.   The 12-month results demonstrated:   • Significant 77% lower TLF rate of 2.1% for DESyne BDS Plus compared to 9.3% for contemporary DES (p=0.03). • No definite or probable stent thrombosis, cardiovascular death, or target vessel myocardial infarction (TV-MI), were observed in DESyne BDS Plus treated patients    Learn more about the results: https://lnkd.in/eNVFUD2U    DESyne BDS Plus is for investigational use only. Not approved in the U.S.   #BDSPlus #Cardiovascular #Medtech #Innovation 

ICYMI: New PINNACLE I study data presented at #EuroPCR 2024 demonstrate effectiveness of the LithiX™ Hertz Contact Intravascular Lithotripsy System’s unique mechanism of action across a broad range of moderate to severe calcified lesion morphologies with more than 90% of lesions demonstrating fractures, overall very deep fracture depth (average depth > 0.80mm) and optimal stent expansion with excellent lumen gain.   Learn more about the results: https://lnkd.in/enu8PvkK    Hertz Contact Intravascular Lithotripsy is for investigational use only. Not approved in the U.S.   #Lithotripsy #Cardiovascular #Medtech #Innovation 

ICYMI: At #EuroPCR 2024, we shared late-breaking two-year data showing significant clinical advantages of the #DynamX® Coronary Bioadaptor System over 3rd generation standard of care drug-eluting stent (DES):   • Continuing separation of target lesion failure (TLF) KM curves, with flattening of the DynamX curve and as expected linear increase for DES  • Significant 65% reduction in TLF rate (1.9% vs. 5.5%; p=0.046)  • Significant 68% reduction in target vessel failure (TVF) rate (1.9% versus 6.0%; p=0.029)   • Significant 78% reduction in TLF rate in left anterior descending (LAD) artery lesions (1.9% vs. 8.7%; p=0.028)   Learn more about the BIOADAPTOR Randomized Controlled Trial (RCT) results: https://lnkd.in/eTwz3A87    CE marked. Not for sale in the U.S.   #Bioadaptor #Medtech #Innovation #Cardiology 

Dr. Mirvat Alasnag on the 5 trials that will impact her practice presented at #EuroPCR. Check out her thoughts on our DESyne #BDSPlus and PINNACLE I data:   #Medtech #Innovation #cardiovascular PMN 1861 Rev A

We’re thrilled that #EuroPCR recognized the two-year BIOADAPTOR RCT results as one of the top three trial updates and DESyne® BDS Plus as a top innovation in the 2024 Highlights presentation!   🎖🏆 Learn more about the data: https://lnkd.in/eDPXjDZ5    #Bioadaptor #Medtech #Innovation #Cardiology #BDSPlus #Cardiovascular 

Congratulations to Dr. Anthony Siu-Fung Wong and the interventional cardiology team from United Christian Hospital, Hong Kong, for selection of their DynamX case as a finalist for the DynamX Xcase Competition 2024! The interventional cardiology team, led by Dr. Tak-Shun Chung, tackled the critical situation of acute left main MI alongside the technical challenge of preserving trifurcation LM anatomy using inverted Culotte LM bifurcation stenting with double bioadaptors. This innovative approach illustrated the culotte technique with mismatched sizes of 2 branches while highlighting the merit of bioadaptors in adapting to dynamic vessel size in AMI settings. The case resulted in good final angiographic results with TIMI 3 flow to all major vessels and branches. Congratulations, Dr. Wong and the United Christian Hospital team, on this remarkable achievement! #XCaseCompetition #DynamX #bioadaptor PMN 1854 Rev A

Coming off a great #EuroPCR 2024! We were thrilled to share data from our transformational technologies and connect with those leading the way in #cardiovascular interventional medicine. A special thanks to our presenters this year! Shigeru Saito, M.D., Flavio Ribichini, Johan Bennett, Mirvat Alasnag, A. Siu Fung Wong, M.D., Ganapathi Palaniappan, Michał Hawranek, Stefan Verheye, Valeria Paradies, Roxana Mehran, stefano galli #Medtech #Innovation